We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03059823
Previous Study | Return to List | Next Study

A Phase 1 Study of MGA012 in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03059823
Recruitment Status : Recruiting
First Posted : February 23, 2017
Last Update Posted : February 1, 2018
Information provided by (Responsible Party):

Brief Summary:
The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGA012 and establish the maximum tolerated dose (MTD) of MGA012 administered on either every two week or every four week schedules of administration among patients with solid tumors. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of MGA012 will also be assessed.

Condition or disease Intervention/treatment Phase
Locally Advanced Solid Tumors Metastatic Solid Tumors Drug: MGA012 Phase 1

Detailed Description:

This is an open-label, multi-center, Phase 1 dose-escalation and dose expansion study to define a MTD, describe preliminary safety, and to assess PK, immunogenicity, and potential anti-tumor activity of MGA012 administered on either every two week or every four week schedules in patients with relapsed/ refractory or unresectable locally/ advanced or metastatic solid tumors.

In the initial phase of the study, two dose schedules will be assessed in dose escalation, once every two weeks and once every four weeks administration of single agent MGA012. Following the establishment of an MTD, additional patients will enroll in expansion cohorts of specific tumor types.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 207 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients With Advanced Solid Tumors
Actual Study Start Date : November 2016
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Arm Intervention/treatment
Experimental: Dose Escalation-Q2W
MGA012 treatment once every 2 weeks
Drug: MGA012
Anti-PD-1 monoclonal antibody
Experimental: Dose Escalation- Q4W
MGA012 treatment once every 4 weeks
Drug: MGA012
Anti-PD-1 monoclonal antibody
Experimental: Expansion Cohort
MGA012 treatment for locally advanced or metastatic solid tumors
Drug: MGA012
Anti-PD-1 monoclonal antibody

Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03 [ Time Frame: 24 months ]
    Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.

  2. MTD [ Time Frame: 24 months ]
    Maximum Tolerated Dose of MGA012

Secondary Outcome Measures :
  1. AUC [ Time Frame: 24 months ]
    Area Under the Plasma Concentration versus Time Curve of MGA012

  2. Cmax [ Time Frame: 24 months ]
    Maximum Plasma Concentration of MGA012

  3. Tmax [ Time Frame: 24 months ]
    Time to reach maximum (peak) plasma concentration of MGA012

  4. Ctrough [ Time Frame: 24 months ]
    Trough plasma concentration of MGA012

  5. Total body clearance of the drug from plasma (CL) of MGA012 [ Time Frame: 24 months ]
  6. Vss [ Time Frame: 24 months ]
    Apparent volume of distribution at steady state of MGA012

  7. t1/2 [ Time Frame: 24 months ]
    Terminal half-life of MGA012

  8. ADA [ Time Frame: 24 months ]
    Percent of patients with anti-drug antibody

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven, locally advanced unresectable or metastatic solid tumors for whom no approved therapy with demonstrated clinical benefit is available or standard treatment was declined.
  • Expansion cohort(s): Progression during or following at least 1, and up to 5, previous systemic therapies, consistent with the standard of care for the specific tumor type.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Life expectancy ≥ 12 weeks
  • Measurable disease
  • Acceptable laboratory parameters

Exclusion Criteria:

  • Symptomatic central nervous system (CNS) metastases.
  • For Cohort Expansion, patients who have previously received an immune checkpoint inhibitor (e.g., anti-PD-L1, anti-PD-1, anti-CTLA-4) are not eligible for this study.
  • Patients with any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic treatment (within the past 2 years), and patients with a history of Grave's disease that are now euthyroid clinically and by laboratory testing.
  • Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the 4 weeks prior to the initiation of study drug administration.
  • Treatment with radiation therapy within 2 weeks prior to the initiation of study drug administration.
  • Clinically significant cardiovascular disease
  • Clinically significant pulmonary compromise, including a requirement for supplemental oxygen use to maintain adequate oxygenation.
  • Presence of active pneumonitis or history of non-infectious pneumonitis.
  • Clinically significant gastrointestinal disorders
  • Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of study drug
  • Known history of positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.
  • Known history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction (PCR)
  • Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed
  • Dementia or altered mental status that would preclude understanding and rendering of informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03059823

Contact: Pepi Pencheva penchevap@macrogenics.com
Contact: Leilei He hel@macrogenics.com

  Show 29 Study Locations
Sponsors and Collaborators
Study Director: Brad Sumrow, MD MacroGenics

Responsible Party: MacroGenics
ClinicalTrials.gov Identifier: NCT03059823     History of Changes
Other Study ID Numbers: CP-MGA012-01
First Posted: February 23, 2017    Key Record Dates
Last Update Posted: February 1, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by MacroGenics:
Solid tumors
Metastatic cancer

Additional relevant MeSH terms: